Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils.
Human peripheral blood eosinophils released eosinophil survival-enhancing activity when stimulated with the calcium ionophore, ionomycin. The release of activity was detected as early as 3 h after stimulation and was inhibited by an immunomodulating agent, cyclosporin A. The survival-enhancing activity was completely abolished by treatment with anti-interleukin 3 (IL-3) and anti-granulocyte/macrophage colony-stimulating factor (GM-CSF) monoclonal antibodies. Moreover, IL-3 and GM-CSF were measurable in ionomycin-stimulated eosinophil supernatants by immunoassay. Eosinophils produced approximately one-half as much IL-3 and one-fifth as much GM-CSF as ionomycin-stimulated mononuclear cells. Neutrophils also produced IL-3 and GM-CSF, but the amounts were less than those produced by eosinophils. These observations suggest a novel role for eosinophils in pathophysiology of allergic inflammation and host defense mechanisms.
Kita
H
H
Division of Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Ohnishi
T
T
Okubo
Y
Y
Weiler
D
D
Abrams
J S
JS
Gleich
G J
GJ
D002470:Cell Survival / Q000187:drug effects; D047208:Eosinophil-Derived Neurotoxin; D004804:Eosinophils / Q000166:cytology / Q000378:metabolism*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007377:Interleukin-3 / Q000378:metabolism*; D015759:Ionomycin / Q000494:pharmacology; D009498:Neurotoxins / Q000378:metabolism; D009504:Neutrophils / Q000166:cytology / Q000378:metabolism*; D012260:Ribonucleases; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D007377:Interleukin-3; D009498:Neurotoxins; D015759:Ionomycin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D047208:Eosinophil-Derived Neurotoxin; D012260:Ribonucleases; D013755:Tetradecanoylphorbol Acetate